An expansion of an ongoing outpatient clinical trial, the study now includes metformin, fluvoxamine and ivermectin as possible treatments of COVID-19 and to prevent “long COVID” An ongoing COVID-19 clinical trial studying the outpatient use of metformin, a generic medication for type 2 diabetes, has expanded and will now be the nation’s first to include fluvoxamine, an antidepressant, and ivermectin, an antiparasitic, as possible treatment options to prevent hospitalization and “long COVID.” Led by the University of Minnesota Medical School, the multi-site clinical trial received new support – $1 million from the Rainwater Charitable Foundation and $500,000 from Fast Grants – to ...